Role for Therapeutic Drug Monitoring During Induction Therapy with TNF Antagonists in IBD

566 Infliximab Concentration and Clinical Outcome in Patients With Ulcerative Colitis

(2015) Walter Reinisch et al.   GASTROENTEROLOGY

Sa2031 Accelerated Clearance of Serum Infliximab During Induction Therapy for Acute Ulcerative Colitis is Associated With Treatment Failure.

(2015) David Kevans et al.   GASTROENTEROLOGY

Su1753 Primary Response to Infliximab in Crohn's Disease Is Associated With the Tnfrsf1a Rs1800693 Gene Polymorphism

(2015) Thomas Billiet et al.   GASTROENTEROLOGY

Tu1167 Infliximab Is More Immunogenic and Reaches Lower Trough Levels in Ulcerative Colitis Patients Compared to Crohn's Disease Patients

(2015) Haggai Bar-yoseph et al.   GASTROENTEROLOGY

Sa1264 Drug Trough Levels and Primary Nonresponse to antiTNF Therapy in Moderate-Severe Crohn Disease. Results of the Optimiza Study

(2014) Ana Echarri et al.   GASTROENTEROLOGY

Sa1237 Prediction of Primary Response to Infliximab in Crohn's Disease: A Matrix-Based Prediction Model

(2014) Thomas Billiet et al.   GASTROENTEROLOGY

Su1393 Primary Non Response to Infliximab in Patients With Inflammatory Bowel Disease

(2014) Konstantinos Papamichael et al.   GASTROENTEROLOGY

Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial

(2014) Séverine Vermeire et al.   LANCET

Primary lack of efficacy of infliximab therapy for rheumatoid arthritis: pharmacokinetic characterization and assessment of switching to tocilizumab

(2014) Shunsuke Mori et al.   Modern Rheumatology

Tailoring anti-TNF therapy in IBD: drug levels and disease activity

(2014) Shomron Ben-Horin et al.   Nature Reviews Gastroenterology & Hepatology

Development of a Universal Anti-Adalimumab Antibody Standard for Interlaboratory Harmonization

(2014) Ann Gils et al.   THERAPEUTIC DRUG MONITORING

Therapeutic drug monitoring in patients with inflammatory bowel disease

(2014) Andres J Yarur   WORLD JOURNAL OF GASTROENTEROLOGY

Association of rs1568885, rs1813443 and rs4411591 polymorphisms with anti-TNF medication response in Greek patients with Crohn’s disease

(2014) Diamantis Thomas   WORLD JOURNAL OF GASTROENTEROLOGY

Pre-existing IgG antibodies cross-reacting with the Fab region of infliximab predict efficacy and safety of infliximab therapy in inflammatory bowel disease

(2013) C. Steenholdt et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Antibody Response to Infliximab and its Impact on Pharmacokinetics can be Transient

(2013) Niels Vande Casteele et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

A Test-based Strategy Is More Cost Effective Than Empiric Dose Escalation for Patients With Crohn's Disease Who Lose Responsiveness to Infliximab

(2013) Fernando S. Velayos et al.   Clinical Gastroenterology and Hepatology

Association Between Pharmacokinetics of Adalimumab and Mucosal Healing in Patients With Inflammatory Bowel Diseases

(2013) Xavier Roblin et al.   Clinical Gastroenterology and Hepatology

The Role of Centralized Reading of Endoscopy in a Randomized Controlled Trial of Mesalamine for Ulcerative Colitis

(2013) Brian G. Feagan et al.   GASTROENTEROLOGY

Subcutaneous Golimumab Induces Clinical Response and Remission in Patients With Moderate-to-Severe Ulcerative Colitis

(2013) William J. Sandborn et al.   GASTROENTEROLOGY

Subcutaneous Golimumab Maintains Clinical Response in Patients With Moderate-to-Severe Ulcerative Colitis

(2013) William J. Sandborn et al.   GASTROENTEROLOGY

Genetic susceptibility to increased bacterial translocation influences the response to biological therapy in patients with Crohn's disease

(2013) Ana Gutiérrez et al.   GUT

Individualised therapy is more cost-effective than dose intensification in patients with Crohn’s disease who lose response to anti-TNF treatment: a randomised, controlled trial

(2013) Casper Steenholdt et al.   GUT

The temporal evolution of antidrug antibodies in patients with inflammatory bowel disease treated with infliximab

(2013) Bella Ungar et al.   GUT

FCGR3A-158 polymorphism influences the biological response to infliximab in Crohn’s disease through affecting the ADCC activity

(2013) Rintaro Moroi et al.   IMMUNOGENETICS

Increased Body Mass Index Is Associated with Earlier Time to Loss of Response to Infliximab in Patients with Inflammatory Bowel Disease

(2013) Jason W. Harper et al.   INFLAMMATORY BOWEL DISEASES

Serum Adalimumab Concentration and Clinical Remission in Patients with Crohnʼs Disease

(2013) Yi-Lin Chiu et al.   INFLAMMATORY BOWEL DISEASES

Genetic polymorphisms of tumour necrosis factor alpha (TNF-α) promoter gene and response to TNF-α inhibitors in Spanish patients with inflammatory bowel disease

(2013) R. López-Hernández et al.   International Journal of Immunogenetics

P500 Fecal loss of infliximab as a cause of lack of response in severe inflammatory bowel disease

(2013) J.F. Brandse et al.   Journal of Crohns & Colitis

High C-reactive protein in Crohn's disease patients predicts nonresponse to infliximab treatment

(2013) Fernando Magro et al.   Journal of Crohns & Colitis

Clinical utility of newly developed immunoassays for serum concentrations of adalimumab and anti-adalimumab antibodies in patients with Crohn’s disease

(2013) Hirotsugu Imaeda et al.   JOURNAL OF GASTROENTEROLOGY

C-reactive protein is an indicator of serum infliximab level in predicting loss of response in patients with Crohn’s disease

(2013) Toshifumi Hibi et al.   JOURNAL OF GASTROENTEROLOGY

Efficacy and safety of adalimumab in Japanese patients with moderately to severely active ulcerative colitis

(2013) Yasuo Suzuki et al.   JOURNAL OF GASTROENTEROLOGY

Relationship between serum infliximab trough levels and endoscopic activities in patients with Crohn’s disease under scheduled maintenance treatment

(2013) Hirotsugu Imaeda et al.   JOURNAL OF GASTROENTEROLOGY

Efficacy, safety, and predictors of response to infliximab therapy for ulcerative colitis: A Korean multicenter retrospective study

(2013) Kang-Moon Lee et al.   JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY

Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis

(2013) Brian G. Feagan et al.   NEW ENGLAND JOURNAL OF MEDICINE

Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease

(2013) William J. Sandborn et al.   NEW ENGLAND JOURNAL OF MEDICINE

The frequency of anti-infliximab antibodies in patients with rheumatoid arthritis treated in routine care and the associations with adverse drug reactions and treatment failure

(2013) S. B. Krintel et al.   RHEUMATOLOGY

UEG Week 2013 Oral Presentations

(2013)   United European Gastroenterology Journal

Long-term outcome of a third anti-TNF monoclonal antibody after the failure of two prior anti-TNFs in inflammatory bowel disease

(2012) P. S. A. Silva et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

C-reactive protein, an indicator for maintained response or remission to infliximab in patients with Crohn's disease: a post-hoc analysis from ACCENT I

(2012) W. Reinisch et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Efficacy and safety of infliximab and adalimumab in Crohn's disease: a single centre study

(2012) F. Zorzi et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Detection of infliximab levels and anti-infliximab antibodies: a comparison of three different assays

(2012) N. Vande Casteele et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Genetic polymorphisms of tumour necrosis factor receptor superfamily 1b and fas ligand are associated with clinical efficacy and/or acute severe infusion reactions to infliximab in Crohn's disease

(2012) C. Steenholdt et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Impact of Antibodies to Infliximab on Clinical Outcomes and Serum Infliximab Levels in Patients With Inflammatory Bowel Disease (IBD): A Meta-Analysis

(2012) Kavinderjit S Nanda et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Therapeutic Drug Monitoring of Tumor Necrosis Factor Antagonists in Inflammatory Bowel Disease

(2012) Ingrid Ordás et al.   Clinical Gastroenterology and Hepatology

Patients Enrolled in Randomized Controlled Trials Do Not Represent the Inflammatory Bowel Disease Patient Population

(2012) Christina Ha et al.   Clinical Gastroenterology and Hepatology

Addition of an Immunomodulator to Infliximab Therapy Eliminates Antidrug Antibodies in Serum and Restores Clinical Response of Patients With Inflammatory Bowel Disease

(2012) Shomron Ben–Horin et al.   Clinical Gastroenterology and Hepatology

Anti-TNF Monoclonal Antibodies in Inflammatory Bowel Disease: Pharmacokinetics-Based Dosing Paradigms

(2012) I Ordás et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Anti-TNF-α biotherapies: perspectives for evidence-based personalized medicine

(2012) Klaus Bendtzen   Immunotherapy

Clinical implications of variations in anti-infliximab antibody levels in patients with inflammatory bowel disease

(2012) Casper Steenholdt et al.   INFLAMMATORY BOWEL DISEASES

Adalimumab for the prevention and/or treatment of post-operative recurrence of Crohn's disease: A prospective, two-year, single center, pilot study

(2012) Konstantinos Papamichael et al.   Journal of Crohns & Colitis

OP10 Importance of trough levels and antibodies on the long-term efficacy of infliximab therapy in ulcerative colitis

(2012) M.T. Arias et al.   Journal of Crohns & Colitis

Second European evidence-based consensus on the diagnosis and management of ulcerative colitis Part 2: Current management

(2012) Axel Dignass et al.   Journal of Crohns & Colitis

Efficacy of Adalimumab as a long term maintenance therapy in ulcerative colitis

(2012) Edel McDermott et al.   Journal of Crohns & Colitis

Observational study on the efficacy of adalimumab for the treatment of ulcerative colitis and predictors of outcome

(2012) Orlando García-Bosch et al.   Journal of Crohns & Colitis

Adalimumab dose escalation and dose de-escalation success rate and predictors in a large national cohort of Crohn's patients

(2012) Filip Baert et al.   Journal of Crohns & Colitis

Infliximab trough levels may predict sustained response to infliximab in patients with Crohn's disease

(2012) Martin Bortlik et al.   Journal of Crohns & Colitis

Development and validation of a homogeneous mobility shift assay for the measurement of infliximab and antibodies-to-infliximab levels in patient serum

(2012) Shui-Long Wang et al.   JOURNAL OF IMMUNOLOGICAL METHODS

Ulcerative colitis

(2012) Ingrid Ordás et al.   LANCET

Crohn's disease

(2012) Daniel C Baumgart et al.   LANCET

Tofacitinib, an Oral Janus Kinase Inhibitor, in Active Ulcerative Colitis

(2012) William J. Sandborn et al.   NEW ENGLAND JOURNAL OF MEDICINE

Ustekinumab Induction and Maintenance Therapy in Refractory Crohn's Disease

(2012) William J. Sandborn et al.   NEW ENGLAND JOURNAL OF MEDICINE

Fc Gamma Receptor CD64 Modulates the Inhibitory Activity of Infliximab

(2012) Kacper A. Wojtal et al.   PLoS One

Mucosal cytokine gene expression profiles as biomarkers of response to infliximab in ulcerative colitis

(2012) Renathe Rismo et al.   SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY

High-dose infliximab for treatment of pediatric ulcerative colitis: A survey of clinical practice

(2012) Roy Nattiv   WORLD JOURNAL OF GASTROENTEROLOGY

Predictors of dose escalation of adalimumab in a prospective cohort of Crohn’s disease patients

(2011) E. Bultman et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Review article: loss of response to anti-TNF treatments in Crohn’s disease

(2011) S. Ben-Horin et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Early clinical remission and normalisation of CRP are the strongest predictors of efficacy, mucosal healing and dose escalation during the first year of adalimumab therapy in Crohn’s disease

(2011) L. S. Kiss et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Baseline tumour necrosis factor alpha levels predict the necessity for dose escalation of infliximab therapy in patients with rheumatoid arthritis

(2011) T. Takeuchi et al.   ANNALS OF THE RHEUMATIC DISEASES

Do Not Assume Symptoms Indicate Failure of Anti–Tumor Necrosis Factor Therapy in Crohn's Disease

(2011) David H. Bruining et al.   Clinical Gastroenterology and Hepatology

Certolizumab Pegol for Active Crohn's Disease: A Placebo-Controlled, Randomized Trial

(2011) William J. Sandborn et al.   Clinical Gastroenterology and Hepatology

Levels of C-reactive Protein Are Associated With Response to Infliximab Therapy in Patients With Crohn's Disease

(2011) Matthias Jürgens et al.   Clinical Gastroenterology and Hepatology

Pharmacokinetic Properties of Infliximab in Children and Adults with Crohn's Disease: A Retrospective Analysis of Data from 2 Phase III Clinical Trials

(2011) Adedigbo A. Fasanmade et al.   CLINICAL THERAPEUTICS

Meta-analysis

(2011) Ziwei Lin et al.   EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY

Adalimumab Induces and Maintains Clinical Remission in Patients With Moderate-to-Severe Ulcerative Colitis

(2011) William J. Sandborn et al.   GASTROENTEROLOGY

Developing an instrument to assess the endoscopic severity of ulcerative colitis: the Ulcerative Colitis Endoscopic Index of Severity (UCEIS)

(2011) Simon P L Travis et al.   GUT

Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial

(2011) W. Reinisch et al.   GUT

Mesenteric fat as a source of C reactive protein and as a target for bacterial translocation in Crohn's disease

(2011) Laurent Peyrin-Biroulet et al.   GUT

Clinical utility of antihuman lambda chain-based enzyme-linked immunosorbent assay (ELISA) versus double antigen ELISA for the detection of anti-infliximab antibodies

(2011) Uri Kopylov et al.   INFLAMMATORY BOWEL DISEASES

Serum albumin concentration: a predictive factor of infliximab pharmacokinetics and clinical response in patients with ulcerative colitis

(2011) A.A. Fasanmade et al.   INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS

Adalimumab as second line anti-tumour necrosis factor alpha therapy for Crohn's disease: A single centre experience

(2011) Michael B. Sprakes et al.   Journal of Crohns & Colitis

Development of a new immunoassay for the accurate determination of anti-infliximab antibodies in inflammatory bowel disease

(2011) Hirotsugu Imaeda et al.   JOURNAL OF GASTROENTEROLOGY

Genetic polymorphisms of tumour necrosis factor receptor superfamily 1A and 1B affect responses to infliximab in Japanese patients with Crohn’s disease

(2010) H. MATSUKURA et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

The CHOICE trial: adalimumab demonstrates safety, fistula healing, improved quality of life and increased work productivity in patients with Crohn’s disease who failed prior infliximab therapy

(2010) S. Lichtiger et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Adalimumab induction and maintenance therapy for patients with ulcerative colitis previously treated with infliximab

(2010) C. Taxonera et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

A Multicenter Experience With Infliximab for Ulcerative Colitis: Outcomes and Predictors of Response, Optimization, Colectomy and Hospitalization

(2010) Abderrahim Oussalah et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Clinical Utility of Measuring Infliximab and Human Anti-Chimeric Antibody Concentrations in Patients With Inflammatory Bowel Disease

(2010) Waqqas Afif et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Disease Activity, ANCA and IL23R Genotype Status Determine Early Response to Infliximab in Patients With Ulcerative Colitis

(2010) Matthias Jürgens et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Increased Response and Remission Rates in Short-Duration Crohn's Disease With Subcutaneous Certolizumab Pegol: An Analysis of PRECiSE 2 Randomized Maintenance Trial Data

(2010) Stefan Schreiber et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

The presence or absence of antibodies to infliximab or adalimumab determines the outcome of switching to etanercept

(2010) A. Jamnitski et al.   ANNALS OF THE RHEUMATIC DISEASES

Pharmacokinetics and Pharmacodynamics of Monoclonal Antibodies

(2010) Diane R. Mould et al.   BIODRUGS

Certolizumab Pegol in Patients With Moderate to Severe Crohn's Disease and Secondary Failure to Infliximab

(2010) William J. Sandborn et al.   Clinical Gastroenterology and Hepatology

Clinical Pharmacokinetics of Therapeutic Monoclonal Antibodies

(2010) Ron J. Keizer et al.   CLINICAL PHARMACOKINETICS

Interleukin-15 and Its Soluble Receptor Mediate the Response to Infliximab in Patients With Crohn's Disease

(2010) Gregory Bouchaud et al.   GASTROENTEROLOGY

Adalimumab for Crohnʼs disease in clinical practice at Mayo clinic: The first 118 patients

(2010) Jason M. Swoger et al.   INFLAMMATORY BOWEL DISEASES

Monitoring functional serum antitumor necrosis factor antibody level in Crohnʼs disease patients who maintained and those who lost response to anti-TNF

(2010) Akihiro Yamada et al.   INFLAMMATORY BOWEL DISEASES

Predictive value of epithelial gene expression profiles for response to infliximab in Crohnʼs disease‡

(2010) Ingrid Arijs et al.   INFLAMMATORY BOWEL DISEASES

The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current management

(2010) A. Dignass et al.   Journal of Crohns & Colitis

Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: Definitions, frequency and pharmacological aspects

(2010) Matthieu Allez et al.   Journal of Crohns & Colitis

A novel method for the detection of antibodies to adalimumab in the presence of drug reveals “hidden” immunogenicity in rheumatoid arthritis patients

(2010) Pauline A. van Schouwenburg et al.   JOURNAL OF IMMUNOLOGICAL METHODS

Importance of Neonatal FcR in Regulating the Serum Half-Life of Therapeutic Proteins Containing the Fc Domain of Human IgG1: A Comparative Study of the Affinity of Monoclonal Antibodies and Fc-Fusion Proteins to Human Neonatal FcR

(2010) Takuo Suzuki et al.   JOURNAL OF IMMUNOLOGY

Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease

(2010) Jean Frédéric Colombel et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cut-off levels and diagnostic accuracy of infliximab trough levels and anti-infliximab antibodies in Crohn's disease

(2010) Casper Steenholdt et al.   SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY

Role of genetics in prediction of disease course and response to therapy

(2010) Severine Vermeire   WORLD JOURNAL OF GASTROENTEROLOGY

The efficacy and safety of a third anti-TNF monoclonal antibody in Crohn’s disease after failure of two other anti-TNF antibodies

(2009) M. ALLEZ et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Anti-adalimumab antibodies in rheumatoid arthritis patients are associated with interleukin-10 gene polymorphisms

(2009) G. M. Bartelds et al.   ARTHRITIS AND RHEUMATISM

TNF-alpha gene expression in colorectal mucosa as a predictor of remission after induction therapy with infliximab in ulcerative colitis

(2009) Trine Olsen et al.   CYTOKINE

Population pharmacokinetic analysis of infliximab in patients with ulcerative colitis

(2009) Adedigbo A. Fasanmade et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Influence of Trough Serum Levels and Immunogenicity on Long-term Outcome of Adalimumab Therapy in Crohn's Disease

(2009) Konstantinos Karmiris et al.   GASTROENTEROLOGY

Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis

(2009) C H Seow et al.   GUT

Mucosal gene signatures to predict response to infliximab in patients with ulcerative colitis

(2009) I. Arijs et al.   GUT

Genome wide association (GWA) predictors of anti-TNFα therapeutic responsiveness in pediatric inflammatory bowel disease

(2009) Marla C. Dubinsky et al.   INFLAMMATORY BOWEL DISEASES

IgG1 heavy chain-coding gene polymorphism (G1m allotypes) and development of antibodies-to-infliximab

(2009) Charlotte Magdelaine-Beuzelin et al.   Pharmacogenetics and Genomics

Individual medicine in inflammatory bowel disease: Monitoring bioavailability, pharmacokinetics and immunogenicity of anti-tumour necrosis factor-alpha antibodies

(2009) Klaus Bendtzen et al.   SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY

Efficacy and complications of adalimumab treatment for medically-refractory Crohn’s disease: analysis of nationwide experience in Scotland (2004-2008)

(2008) G. T. HO et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Experience of maintenance infliximab therapy for refractory ulcerative colitis from six centres in England

(2008) E. A. RUSSO et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Early clinical experience with adalimumab in treatment of inflammatory bowel disease with infliximab-treated and naïve patients

(2008) A. SWAMINATH et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis

(2008) T R D J Radstake et al.   ANNALS OF THE RHEUMATIC DISEASES

Non-response to infliximab may be due to innate neutralizing anti-tumour necrosis factor-α antibodies

(2008) E. C. Ebert et al.   CLINICAL AND EXPERIMENTAL IMMUNOLOGY

Proteomics for prediction and characterization of response to infliximab in Crohn's disease: A pilot study

(2008) Marie-Alice Meuwis et al.   CLINICAL BIOCHEMISTRY

Withdrawal of Immunosuppression in Crohn's Disease Treated With Scheduled Infliximab Maintenance: A Randomized Trial

(2008) Gert Van Assche et al.   GASTROENTEROLOGY

Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort

(2008) F Schnitzler et al.   GUT

Successful induction of clinical response and remission with certolizumab pegol in Crohnʼs disease patients refractory or intolerant to infliximab: A real-life multicenter experience of compassionate use

(2008) Silvio Danese et al.   INFLAMMATORY BOWEL DISEASES

Long-term outcome after infliximab for refractory ulcerative colitis

(2008) Marc Ferrante et al.   Journal of Crohns & Colitis

Tumor Necrosis Factor-Alpha Binding Capacity and Anti-Infliximab Antibodies Measured by Fluid-Phase Radioimmunoassays as Predictors of Clinical Efficacy of Infliximab in Crohn's Disease

(2007) Mark A. Ainsworth et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

The clinical response to infliximab in rheumatoid arthritis is in part dependent on pretreatment tumour necrosis factor   expression in the synovium

(2007) C A Wijbrandts et al.   ANNALS OF THE RHEUMATIC DISEASES